Bridget Hoyt

Hardik Thakkar, MSPAS, PA-C, discusses the ways in which NPs and PAs can benefit from each other’s specialized training.

The FDA approved the combination of relacorilant and nab-paclitaxel in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

The FDA has granted traditional approval to nivolumab in cHL after autologous HSCT and brentuximab vedotin and after 3 or more lines of therapy.

Mark S. Lin, MSN, FNP-BC, highlighted nursing considerations for breast reconstruction surgery in breast cancer.

Don S. Dizon, MD, FACP, FASCO, shared insights on what pregnancy looks like with a breast cancer diagnosis and what those considering pregnancy should know.

Samantha Shenoy, NP, MSN, provides nursing guidance on teclistamab/subcutaneous daratumumab’s second-line approval in multiple myeloma.

A real-world study found rates of toxicity-related T-DXd discontinuation in HER2-low metastatic breast cancer similar to those observed in DESTINY-Breast04.

Teclistamab plus daratumumab hyaluronidase-fihj has been approved for patients with relapsed/refractory multiple myeloma as part of the CNPV program.

ONS is developing a collection of photos of dermatologic toxicities across skin types to address disparities in the care of patients of color with cancer.

Zongertinib has been granted accelerated approval in NSCLC harboring HER2 TKD mutations as part of the Commissioner’s National Priority Voucher pilot program.

The FDA has approved encorafenib plus cetuximab and fluorouracil-based chemotherapy in patients with BRAF V600E-positive metastatic colorectal cancer.

The FDA has approved acalabrutinib plus venetoclax in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

New clinical data highlight the impact of infusion timing on NSCLC survival, alongside updated ASCO guidelines and FDA RMAT status for inhaled KB707.

The FDA approved IV and subcutaneous pembrolizumab with paclitaxel with or without bevacizumab for patients with platinum-resistant ovarian cancers.

The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk severe or fatal toxicities.

A look at the current state of cancer, from survival rates to federal research budgets.

The FDA approved a larger vial size of nelarabine for the treatment of pediatric and adult patients with T-ALL and T-LBL.

Updates in ovarian cancer include multiple fast track designations and breakthrough therapy status for new drugs in the clinical space.

The FDA approved subcutaneous daratumumab/VRd in patients with newly diagnosed multiple myeloma who are not eligible for ASCT. Here’s what you should know.

Plus, a phase 1 breast cancer vaccine, updated NCCN guidelines, and a combination with standard-of-care potential in triple-negative breast cancer.

When patients with RCC progress on a TKI/IO combination, advanced practice providers use patient experience to inform treatment decisions.

Margarita Huober, AGNP, AOCNP, explains that understanding a patient on an individual level leads to more informed care decisions in RCC.

Findings from a real-world, head-to-head comparison show greater colorectal cancer risk reduction and safety with the use of a GLP-1RA vs aspirin.

Look back at the top 5 updates for oncology nurses and advanced practices providers published in 2025.

The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj across all amivantamab indications.

The FDA has greenlit treatment with rucaparib for previously treated patients with BRCA-mutated metastatic castration-resistant prostate cancer.

The FDA has approved niraparib and abiraterone acetate with prednisone for the treatment of patients with BRCA2-mutated metastatic hormone-sensitive prostate cancer.

Phase 2 data demonstrated similar pharmacokinetic profiles between subcutaneous azacitidine and an oral combination of azacitidine and cedazuridine.

Patients with relapsed/refractory large B-cell lymphoma treated with glofitamab or epcoritamab experienced early disease progression.

Dexamethasone reduced the severity of ICANS but did not impact the rates of ICANS or CRS in patients with LBCL receiving axi-cel.